# Pizarra — PT-pseudo_36c92fb424ac (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_36c92fb424ac
Task: 1

Encounter: Urology - outpatient on 20 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.32 ng/mL/yr
  - Prior PSA: 5.4 ng/mL
  - Prostate volume: 79.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7697653 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Obesity (BMI >30), Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Obesity (BMI >30), Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 6 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 79 mL. csPCa 0.77.

Vitals: weight 94 kg, height 184 cm, BMI 27.8, BP 123/65 mmHg, HR 58 bpm. Smoking: Ex-smoker (36 pack-yr, quit 2005).

Chief complaint: Ongoing PSA elevation combined with a previous negative biopsy necessitates clinical reassessment.

History: Initial evaluation for elevated PSA began in late 2022. This 67-year-old gentleman has completed a negative biopsy and returns now for reassessment. A retired police officer, he is married and resides alone. He walks daily for 45 minutes and abstains completely from alcohol. Lower urinary tract symptoms (IPSS 19/35) remain moderate and are effectively managed with tamsulosin. His active medications consist of atorvastatin, simvastatin, rosuvastatin, paracetamol PRN, and tamsulosin. Comorbidities include hypercholesterolaemia, chronic kidney disease, obesity (BMI >30), osteoarthritis, and benign prostatic hyperplasia. He quit smoking in 2005 after a 36 pack-year history. He completed a six-session physiotherapy regimen for stable lower back discomfort that holds no relation to his urological concerns. Routine podiatry visits maintain his foot health. Residing over 90 minutes from the facility, he favours telephone consultations when medically suitable.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland appears symmetrically enlarged without palpable nodules. General assessment remains unremarkable. Vital signs are stable. There are no clinical indicators of systemic disease or lymphadenopathy.

Patient info: retired police officer; Married; Lives alone.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 45 min/day; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Podiatry — routine foot care; Physiotherapy — lower back, six sessions.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.60 +/- 0.21   (95% CI 0.17-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.18  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 4.0 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=6.0, age=67.0, psad=0.08, dre_ord=0.0, vol=79.0, n_pmhx=5.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used the visible panel data (PI-RADS 4, PSA 6.0, prior negative biopsy, PSA velocity 1.32 ng/mL/yr, csPCa probability 0.77) and could not account for the context of the retrieved documents. Specifically, it did not weigh the patient's comorbidities (CKD, Obesity), the specific PSA density (0.08 ng/mL²), or the DRE finding (Normal), which might modify the risk profile suggested by the PI-RADS 4 score.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a wide uncertainty interval (0.60 +/- 0.21), meaning the classifier is genuinely unable to distinguish between the two outcomes based on the limited input. The guideline criterion suggests that a PI-RADS 4-5 lesion mandates re-biopsy, but the prior cannot confirm if the current PI-RADS 4 lesion is stable or if other factors (like PSA velocity) warrant exclusion.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context on initial evaluation and follow-up
laboratory panel - full panel
family-history of prostate cancer (anamnesis)

GUIDELINE ANCHOR
The guideline states that a PI-RADS 4-5 lesion mandates a repeat biopsy to confirm histological progression before a change in treatment strategy.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_36c92fb424ac", "radiology_report": "Subject: Multiparametric MRI Prostate | Date: 15 Jan 2025 | Institution: Catharina Ziekenhuis (Eindhoven)\n\nClinical Context:\nA 67-year-old gentleman with a PSA reading of 6.0 ng/mL and a history of a negative biopsy warrants re-evaluation due to a rising PSA trajectory and clinical suspicion of clinically significant prostate cancer.\n\nImaging Characteristics:\nThe gland occupies 79.0 mL of volume. T2-weighted sequences highlight a focal hypointense abnormality, roughly 18 mm, situated in the right peripheral zone at mid-gland height. Diffusion-weighted imaging shows pronounced restriction with matching low apparent diffusion coefficient signal. Dynamic contrast phases capture early, focal enhancement compared to adjacent parenchyma. Seminal vesicles remain clear; no capsular breach or suspicious nodal enlargement is evident.\n\nIMPRESSION:\nPI-RADS 4 lesion in the right peripheral zone mid-gland.\nProstate volume 79.0 mL; PSA density 0.08 ng/mL/mL.\ncsPCa predicted probability 0.7697653."}
get_psa_trend
{"case_id": "PT-pseudo_36c92fb424ac", "psa_trend": [{"date": "Nov 2023", "val": 2.5}, {"date": "Jun 2024", "val": 1.4}, {"date": "Jan 2025", "val": 6.0}]}
get_previous_notes
{"case_id": "PT-pseudo_36c92fb424ac", "previous_notes": [{"date": "31 Jan 2023", "author": "Dr. K. Bakker (GP)", "text": "Initial laboratory screening identified a PSA level of 3.9 ng/mL. Digital palpation showed no abnormalities. A multiparametric MRI was ordered to evaluate potential suspicious areas. After reviewing the risks associated with a biopsy, the patient opted to pursue imaging first."}, {"date": "26 Jan 2024", "author": "Dr. K. Bakker (GP)", "text": "Subsequent laboratory analysis conducted in June 2024 indicated a PSA rise to 5.4 ng/mL. Earlier imaging had identified a PI-RADS 4 lesion, prompting a systematic biopsy that ultimately yielded negative results for cancer. Owing to the sustained PSA elevation alongside those radiological markers, the individual is being redirected to urology for further assessment."}]}
get_lab_results
{"case_id": "PT-pseudo_36c92fb424ac", "laboratory_results": [{"name": "PSA", "val": "6.0 ng/mL", "date": "09 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.72 ng/mL", "date": "09 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "12%", "date": "09 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "15.2 g/dL", "date": "09 Dec 2024", "flag": ""}, {"name": "WBC", "val": "8.4 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "195 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "137 umol/L", "date": "09 Dec 2024", "flag": "H"}, {"name": "eGFR", "val": "<60 mL/min/1.73m2", "date": "09 Dec 2024", "flag": "L"}, {"name": "Testosterone", "val": "11.5 nmol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "86 U/L", "date": "09 Dec 2024", "flag": ""}, {"name": "LDH", "val": "167 U/L", "date": "09 Dec 2024", "flag": ""}]}

NOT RETRIEVED
The pathology report was not retrieved because the task description indicated it was not on file for this specific decision.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 4 lesion in the right peripheral zone mid-gland.
- PSA trend: Rising trajectory from 2.5 ng/mL (Nov 2023) to 6.0 ng/mL (Jan 2025).
- Previous notes: Patient was redirected to urology due to sustained PSA elevation and PI-RADS 4 finding.

AGAINST sampling this patient now:
- DRE findings: Normal.
- Lab results: eGFR <60 mL/min/1.73m2 (Chronic Kidney Disease).

WHERE THIS LEANS
The evidence strongly supports re-biopsy based on the PI-RADS 4 finding and the rising PSA trend, aligning with the EXPERT-PROTOCOL guideline criterion. This leans toward a recommendation for targeted sampling.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The guideline criterion mandates biopsy due to the PI-RADS 4 lesion, which is supported by the retrieved mpMRI report. This decision is reinforced by the rising PSA trend from 2.5 ng/mL to 6.0 ng/mL and the previous notes indicating redirection to urology. The statistical prior suggested biopsy, and the retrieved evidence converges on this recommendation, despite the patient's CKD comorbidity.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=important
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
